Wednesday Afternoon’s Analyst Upgrades and Downgrades: Inovio Pharmaceuticals, McDonald’s, VBI Vaccines, Wingstop and More
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
Markets were somewhat mixed on Wednesday with the Dow Jones industrials and S&P 500 edging higher with the Nasdaq slipping. Although COVID-19 cases are on the rise globally due to the omicron variant, investors seem to be taking it in stride, as the S&P 500 hit a fresh all-time high earlier this week. With only a few days left in 2021, it remains to be seen if the Santa rally will kick into gear.
24/7 Wall St. is reviewing some big analyst calls seen on Wednesday. We have included the latest call on each stock, as well as a recent trading history and the consensus targets among analysts. Note that analyst calls seen earlier in the day were on Adobe, Paysafe, Riot Blockchain, Shopify, Tesla and more.
Altimmune Inc. (NASDAQ: ALT): Jefferies resumed coverage with a Buy rating and a $30 price target. Shares were trading around $9 on Wednesday. The 52-week range is $8.10 to $24.61.
Brooklyn ImmunoTherapeutics Inc. (NASDAQ: BTX): Cantor Fitzgerald initiated coverage with an Overweight rating and a $9 price target. The 52-week trading range is $3.59 to $80.67, and shares were last seen trading near $4.
[nativounit]
Cintas Corp. (NASDAQ: CTAS | CTAS Price Prediction): Argus reiterated a Buy rating and raised the price target to $490 from $410. The 52-week range is $314.62 to $461.44, and shares were trading near $444 apiece.
Co-Diagnostics Inc. (NASDAQ: CODX): Sidoti started coverage with a Buy rating and a $14 price target. Shares were trading around $9 on Wednesday, and the consensus target price is $22.00.
Inovio Pharmaceuticals Inc. (NASDAQ: INO): Jefferies resumed coverage with a Hold rating but lowered the $8 price target to $6. Shares were trading around $5 on Wednesday, and the consensus target price is $13.88.
McDonald’s Corp. (NYSE: MCD): Tigress Financial boosted its $271 target price to $314 and maintained its Buy rating.
Orchard Therapeutics PLC (NASDAQ: ORTX): Cantor Fitzgerald resumed coverage with an Overweight rating and cut the price target to $9 from $12. Shares were trading around $1 on Wednesday, and the 52-week trading range is $1.16 to $9.08.
VBI Vaccines Inc. (NASDAQ: VBIV): Jefferies resumed coverage with a Buy rating and trimmed the price target to $6 from $7. The 52-week trading range is $2.09 to $4.83, and shares were trading near $2.
Wingstop Inc. (NASDAQ: WING): Benchmark initiated coverage with a Hold rating. Shares were trading around $172 on Wednesday, and the 52-week trading range is $112.49 to $187.35.
[recirclink id=1020732]
Five Dividend Aristocrats are in sectors that have underperformed in 2021 or are solid plays as investors continue to deal with both rising inflation and the potential for rising interest rates in 2022. They could be exceptional stocks to own if the going gets rough next year.
Meet the preliminary Dogs of the Dow for 2022. Also, have a look at where meme stocks BlackBerry and Palantir have been and where they could be headed.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.
